Stock DMA DIAMEDICA INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases DiaMedica Inc. Toronto S.E.

Equities

DMA

CA25253T1075

End-of-day quote Toronto S.E.
Other stock markets
- CAD - Intraday chart for DiaMedica Inc.
Apr. 17 DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment MT
Apr. 17 DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
BU
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
BU
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
BU
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
BU
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
BU
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
BU
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
BU
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
BU
DiaMedica Therapeutics to Participate at Lake Street's 7th Annual Best Ideas Growth Conference
AQ
DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
BU
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
BU
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
BU
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
BU
DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
BU
DiaMedica Therapeutics Announces $37.5 Million Private Placement
BU
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
BU
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
BU
DIAMEDICA THERAPEUTICS INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
DIAMEDICA THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K)
AQ
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DMAC Stock
  4. DMA Stock
  5. News DiaMedica Inc.
  6. Press Releases